THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 17, pp. 11678–11684, April 28, 2006


# NFκB Negatively Regulates Interferon-induced Gene Expression and Anti-influenza Activity*

Received for publication, December 13, 2005, and in revised form, February 28, 2006 Published, JBC Papers in Press, March 3, 2006, DOI 10.1074/jbc.M513286200

**Lai Wei[‡§], Matthew R. Sandbulte[¶], Paul G. Thomas[‖], Richard J. Webby[¶], Ramin Homayouni[§], and Lawrence M. Pfeffer[‡1]**

*From the Departments of [‡]Pathology and Laboratory Medicine and of [§]Neurology, University of Tennessee Health Science Center and University of Tennessee Cancer Institute, Memphis, Tennessee 38163 and the Departments of [¶]Infectious Diseases and of [‖]Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105*

**Interferons (IFNs) are antiviral cytokines that selectively regulate gene expression through several signaling pathways including nuclear factor κB (NFκB). To investigate the specific role of NFκB in IFN signaling, we performed gene expression profiling after IFN treatment of embryonic fibroblasts derived from normal mice or mice with targeted deletion of NFκB p50 and p65 genes. Interestingly, several antiviral and immunomodulatory genes were induced higher by IFN in NFκB knock-out cells. Chromatin immunoprecipitation experiments demonstrated that NFκB was basally bound to the promoters of these genes, while IFN treatment resulted in the recruitment of STAT1 and STAT2 to these promoters. However, in NFκB knock-out cells IFN induced STAT binding as well as the binding of the IFN regulatory factor-1 (IRF1) to the IFN-stimulated gene (ISG) promoters. IRF1 binding closely correlated with enhanced gene induction. Moreover, NFκB suppressed both antiviral and immunomodulatory actions of IFN against influenza virus. Our results identify a novel negative regulatory role of NFκB in IFN-induced gene expression and biological activities and suggest that modulating NFκB activity may provide a new avenue for enhancing the therapeutic effectiveness of IFN.**

Type I IFNs[2] (IFNα, IFNβ, IFNω, and IFNτ) are multifunctional cytokines that are critical in the host defense to infectious agents by modulating innate and adaptive immune responses. IFNs induce their biological effects by regulating the expression of a family of early response genes, called IFN-stimulated genes (ISGs), through JAK-mediated tyrosine-phosphorylation of the STAT factors, STAT1 and STAT2. The phosphorylated STAT proteins dimerize, translocate into the nucleus, and bind to the conserved IFN-stimulus response element (ISRE) within the promoters of ISGs (1). In addition, transcription factors of the IFN regulatory factor (IRF) family have been shown to regulate ISG expression (2). Accumulating evidence indicates that IFNs also activate the nuclear factor κB (NFκB) transcription factor in a serine/threonine kinase-dependent signaling pathway (3, 4).

The mammalian NFκB proteins, p50, p52, RelA (p65), RelB, and c-Rel, form homodimers and heterodimers to regulate the expression of genes involved in the immune response, inflammation and cell survival (5). In most cell types, the predominant form of NFκB, the p50:p65 heterodimer, is bound to IκB inhibitory proteins in the cytoplasm of unstimulated cells. Similar to various other stimuli, IFNα/β activates a phosphatidylinositol 3-kinase/Akt pathway, which results in the dissociation of the inactive cytosolic NFκB·IκB complexes followed by NFκB nuclear translocation and DNA binding (3, 4). We previously demonstrated that mouse embryonic fibroblasts (MEFs) derived from mice with germ line deletions of the p50 and p65 genes were resistant to IFN-induced NFκB activation and were sensitized to the antiviral action of IFNβ against vesicular stomatitis virus (6).

The present study was undertaken to further define the role of NFκB in IFN-induced gene expression and the biological actions of IFN. Gene expression profiling identified 35 ISGs whose induction was highly regulated by NFκB. A subset of genes that were induced higher by IFN in NFκB knock-out (NFκB-KO) cells encoded GTP-binding and antigen presentation proteins, which play critical roles in the antiviral and immunomodulatory activities of IFN, respectively. Quantitative RT-PCR demonstrated that these ISGs were induced more rapidly and at significantly lower IFN concentrations in NFκB-KO cells relative to wild-type (WT) MEFs. Chromatin immunoprecipitation (ChIP) assays demonstrated that NFκB dimers containing p50 and p65 were basally bound to the promoters of these ISGs. IFN induced the binding of STAT1 and STAT2 to these promoters. However, the kinetics of ISG induction in NFκB-KO MEFs by IFN correlated with the promoter binding of IRF1. These results suggest that IFN induction of these genes is negatively regulated by NFκB. We also found that NFκB suppressed not only the direct antiviral action of IFN against influenza virus but also IFN-induced influenza-specific MHC class I antigen presentation. Together, our results suggest that NFκB not only regulates the induction of a subset of IFN-induced genes but also the antiviral and immunomodulatory activities of IFN.

## EXPERIMENTAL PROCEDURES

*Biological Reagents and Cell Culture*—Recombinant rat IFNβ was obtained from Biogen-Idec, Inc. (7). Antibodies directed against the following proteins were used: p65, p50, IRF1, STAT1, STAT2, Tap1, and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA); Mx1 was from Dr. Otto Haller; phospho-Stat2 was from Upstate Biotechnology (Charlottesville, VA); and TFIIB was from ActiveMotif (Carlsbad, CA). WT and NFκB-KO MEFs (8) were plated at $1 \times 10^4$ cells/cm$^2$ every 3 days in Dulbecco's modified Eagle's medium supplemented with 10% defined bovine calf serum (Hyclone Laboratories, Logan, UT), and 100 units/ml penicillin G, and 100 μg/ml streptomycin.

*RNA Preparation and Microarray Analysis*—Total cellular RNA from control and IFNβ-treated (2,500 units/ml for 5 h) WT or

* This work was supported by National Institutes of Health Grant CA73753 (to L. M. P.) and by funds from the Muirhead Chair Endowment at the University of Tennessee Health Science Center. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[1] To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, 930 Madison Ave. (Rm. 530), Memphis, TN 38163. Tel.: 901-448-7855; Fax: 901-448-6979; E-mail: lpfeffer@utmem.edu.

[2] The abbreviations used are: IFN, interferon; ISG, IFN-stimulated gene; JAK, Janus kinase; STAT, signal transducers and activators of transcription; IRF, IFN regulatory factor; MEF, mouse embryonic fibroblast; RT, real-time; WT, wild-type; ChIP, chromatin immunoprecipitation; MHC, major histocompatibility complex; DMEM, Dulbecco's modified Eagle's medium; IL, interleukin; NF-κB, nuclear factor κB.

NFκB-KO MEFs was extracted with TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Approximately 10 μg of RNA was submitted to Genome Explorations Inc. (Memphis, TN) for labeling and hybridization to murine U74Av2 GeneChips (Affymetrix Inc.) according to the manufacturer's protocols. Expression values were determined using Affymetrix Microarray Suite (MAS) 5.0 software. All data analysis was performed using GeneSpring software 7.0 (Silicon Genetics, Inc.). The MAS 5.0 gene expression values for each gene were normalized as described previously (6). Fold induction by IFN was calculated in matched pairs of WT and NFκB-KO MEFs, respectively. The average of fold induction from three independent sets of GeneChip data for both WT and NFκB-KO MEFs was subjected to non-parametric *t* test. The difference of fold induction for each gene by IFN was calculated by subtracting fold induction in WT MEFs from fold induction in NFκB-KO MEFs.

*Quantitative Real-time (RT)-PCR*—Total RNA was isolated from untreated and IFNβ-treated MEFs using TRIzol reagent. Quantitative RT-PCR was performed on a SmartCycler (Cepheid, Sunnyvale, CA) using the AccessQuick™ RT-PCR system (Promega, Madison, WI) and SYBR Green I (Molecular Probes, Eugene, OR) according to the manufacturer's instructions. The following forward and reverse primers were used for each gene: *Ifi47*, 5′-CTCGGACGGTTCTTCTTATC-3′ (forward) and 5′-AGCACCCTCCTCTCTTCATG-3′ (reverse); *Tap1*, 5′-TTGCCTGAACAAGAACAGTG-3′ (forward) and 5′-AAGTTCCCCCTTGATGTCTG-3′ (reverse); *Mx1*, 5′-GACTACCACTGAGATGACCC-3′ (forward) and 5′-CTCTATTTCCTCCCCAAATG-3′ (reverse); β-actin, 5′-AAGGAGATTACTGCTCTGGC-3′ (forward) and 5′-ACATCTGCTGGAAGGTGGAC-3′ (reverse).

Reverse transcription was performed at 48 °C for 45 min, and RT-PCR cycling parameters were as follows: denaturation at 95 °C for 2 min, amplification at 94 °C for 30 s, and 62 °C for 30 s for 35 cycles. The product size was initially monitored by agarose gel electrophoresis and melting curves were analyzed to control for specificity of PCR reactions. The data on IFN-induced genes was normalized to the expression of the housekeeping gene β-actin. The relative units were calculated from a standard curve, plotting three different concentrations against the PCR cycle number at the cycle threshold (with a 10-fold increment equivalent to ~3.1 cycles).

*Immunoblotting*—At various times after IFNβ treatment (1,000 units/ml), MEFs were lysed directly in radioimmunoprecipitation assay buffer (whole cell lysate), or nuclear extracts were prepared with the NE-PER kit (Pierce). Equivalent amounts of protein were subjected to SDS-PAGE. Proteins were transferred to nitrocellulose membranes, immunoblotted for Tap1, Mx1, β-actin, or TFIIB and visualized by enhanced chemiluminescence (Pierce).

*Chromatin Immunoprecipitation*—ChIP experiments were performed using the ChIP-IT™ chromatin immunoprecipitation kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions. DNA was sheared to an average size of ~600 bp. The following forward and reverse primers were used for each gene: *Ifi47*, 5′-CATCTCTTTCATCCTTGTCC-3′ (forward) and 5′-AGAAGCCTGGAAGATTCAAG-3′ (reverse); *Tap1*, 5′-CACTTCTAGTCAGCTCCACC-3′ (forward) and 5′-AGAGTCTGGTCCTAGCCTGG-3′ (reverse); *Mx1*, 5′-CCAGAGGAGAATTGAAACCG-3′ (forward) and 5′-TCCCAACCTCAGTACCAAGC-3′ (reverse).

*Antiviral Assay*—To determine the cellular sensitivity to the ability of IFN to reduce influenza A virus titer, cell cultures were preincubated overnight with IFN, followed by infection with influenza A/Puerto Rico/8/34 (PR8) virus for 1 h at 1 plaque-forming unit per cell. At 24 h

**TABLE 1**
**ISGs regulated by NFκB in WT and NFκB-KO MEFs**

| Entrez gene ID | Gene symbol | WT fold induction[c] | NFκB-KO fold induction[c] | Fold induction difference[d] |
|---|---|---|---|---|
| 15953 | *Ifi47*[a] | 111.8 | 295.5 | *183.6* |
| 17857 | *Mx1*[a] | 114.3 | 286.6 | *172.2* |
| 17858 | *Mx2*[a] | 35.0 | 56.9 | *21.9* |
| 14468 | *Gbp1*[a] | 38.5 | 779.5 | *741.0* |
| 14469 | *Gbp2*[a] | 411.2 | 175.6 | *−235.6* |
| 21354 | *Tap1*[b] | 11.87 | 34.35 | *22.5* |
| 21355 | *Tap2*[b] | 10.58 | 2.92 | *−7.7* |
| 16913 | *Pmsb8*[b] | 38.24 | 58.96 | *20.7* |
| 16912 | *Pmsb9*[b] | 10.29 | 18.43 | *8.1* |
| 15018 | *H2-Q7*[b] | 19.83 | 52.78 | *33.0* |

[a] NFκB-regulated GTP-binding ISGs.
[b] NFκB-regulated antigen presentation ISGs.
[c] Fold induction of genes by IFN was the average of the ratio of gene induction in IFN-treated/control MEFs from three independent sets of GeneChip data.
[d] The difference of fold induction of genes by IFN was calculated by subtracting fold induction in WT MEFs from fold induction in NFκB-KO MEFs.




FIGURE 1. **Dose-dependent induction by IFN of *Ifi47* (*A*), *Tap1* (*B*), and *Mx1* (*C*) expression.** Real-time PCR was performed on cDNAs prepared from MEFs (WT, NFκB-KO, and p50-KO) treated with IFNβ at varying concentrations for 5 h. Gene expression was normalized to actin expression in each sample. Data are shown as fold induction relative to untreated fibroblasts and are mean values ± the S.E. ($n = 3$).




FIGURE 2. **Time course of IFN-induced gene expression.** *A*, real-time PCR was performed for *Ifi47*, *Tap1*, *Mx1*, and *IRF1* using cDNAs prepared from MEFs treated with IFN$\beta$ at 1,000 units/ml for varying times. Gene expression was normalized to actin expression in each sample. Data are shown as fold induction relative to untreated fibroblasts and are mean values $\pm$ the S.E. ($n = 3$). *B*, immunoblotting was performed with indicated antibodies on whole cell or nuclear lysates prepared from MEFs treated with IFN$\beta$ (1,000 units/ml) for the indicated times. Protein loading was evaluated by immunoblotting with anti-actin (cell) or -TFIIB (nuclear) antibodies. Similar results were obtained in at least two independent experiments.

post-infection, the virus yield in the medium was assayed by plaque formation on Madin-Darby canine kidney cells as described previously (9).

*Influenza-specific Immune Assays*—To assay for MHC class I functional expression, $5 \times 10^3$ WT or NFκB MEF cells were co-cultured with $1 \times 10^5$ 4-39 hybridoma cells in individual wells of 96-well plates for 24 h in a 1:1 mixture of DMEM and Complete tumor medium containing 0.1 $\mu$g/ml $D^b$NP-366 peptide and IFN$\beta$. The 4-39 hybridoma line reacts positively by IL-2 production with the immunodominant $D^b$NP-366 peptide but negatively with $D^b$PA-224, $K^b$PB1–703, $K^b$NS2–114, and $D^b$PB1-F2–62 peptides (10, 11). Alternatively, to assay for MHC class I antigen processing and presentation following infection with influenza virus, $5 \times 10^3$ MEF cells were cultured in individual wells of a 96-well plate in DMEM overnight in the presence or absence of IFN$\beta$. Then MEF cells were infected with PR8 influenza A virus at 1 plaque-forming unit/cell in serum-free DMEM for 1 h, followed by co-culture with 4-39 hybridoma cells ($1 \times 10^5$) without or with IFN$\beta$ in DMEM plus Complete tumor medium (1:1) for 24 h. IL-2 production, which in this assay correlates directly to the MHC class I expression on the MEF cell surface, was measured by enzyme-linked immunosorbent assay using purified anti-IL-2 and biotin-anti-IL-2 (Pharmingen) antibodies following the manufacturer's directions.

## RESULTS

*Identification of ISGs That Are NFκB-dependent*—We previously reported that NFκB plays a role in regulating ISG expression (6). Subsequently, a functional genomics approach was used to monitor the role of NFκB in gene expression changes induced by IFN. For these experiments, we used fibroblasts derived from mice with germ line deletions of the p50 and p65 genes. These MEFs were shown to be resistant to IFN-induced NFκB activation (6) and hence can be considered as




FIGURE 3. **Transcription factors binding profiles to NFκB-regulated ISG promoters in WT and NFκB-KO fibroblasts.** ChIP assays were performed on extracts from control and IFN-treated MEFs using the indicated antibodies for precipitation and various primers that targeted specific regions in the *Ifi47* (*A*), *Tap1* (*B*), and *Mx1* (*C*) promoters (see "Experimental Procedures"). Similar results were obtained in at least three independent experiments.

NFκB-KO. In contrast, MEFs expressing p50 and p65 genes were IFN-responsive and considered WT. In three independent experiments, WT and NFκB-KO MEFs were treated in the presence or absence of IFNβ (2,500 units/ml for 5 h), and total RNA was extracted, labeled, and hybridized to murine U74Av2 GeneChips (Affymetrix). Control cultures received no IFN but were treated in parallel. Expression values were determined using Affymetrix Microarray Suite (MAS) 5.0 software, and the data were filtered and analyzed using GeneSpring software 7.0 (Silicon Genetics, Inc.) as described previously (6).

After data processing, a total of 7,412 probe sets were used to compare gene expression between MEFs differing with respect to genotype (NFκB-KO and WT) and treatment (control and IFN treatment). Parametric two-way analysis of variance ($p < 0.05$, $n = 3$ for each group) identified 1,375 probe sets whose expression was different between any two of four groups (control WT MEFs, IFN-treated WT MEFs, control NFκB-KO MEFs, IFN-treated NFκB-KO MEFs). The induction of 35 genes by IFN was significantly ($p < 0.05$, non-parametric *t* test, $n = 3$ for each group) different between WT and NFκB-KO cells. Functional classification of NFκB-regulated ISGs using Expression Analysis Systematic Explorer analysis (12) revealed that genes encoding GTP-binding and antigen presentation proteins were significantly overrepresented (variant one-tailed Fisher exact probability test, Expression Analysis System-

atic Explorer scores < 0.01). The NFκB-regulated GTP-binding ISGs included the 65–67-kDa guanylate-binding proteins (*Gbp1* and *Gbp2*), the Mx proteins (*Mx1* and *Mx2*), and the 47-kDa GTPase *Ifi47* (also called *Irg47*) (13). GBPs play important roles in resistance to viruses (14–16), as well as intracellular protozoa and bacteria (13). On the other hand, the NFκB-regulated antigen presentation ISGs (*Tap1*, *Tap2*, *Psmb9/Lmp2*, and *Psmb8/Lmp7*) are involved in degrading intracellular proteins into antigenic peptides and contribute to the transport of these peptides to endoplasmic reticulum where they bind to the assembled MHC class I molecules (17). As shown in Table 1, *Gbp1*, *Ifi47*, *Mx1*, *Mx2*, *Tap1*, *Psmb9/Lmp2*, and *Psmb8/Lmp7* were induced by IFN to a greater extent in NFκB-KO MEFs than in WT MEFs, while *Gbp2* and *Tap2* were induced more in WT MEFs than in NFκB-KO MEFs. These findings suggested that NFκB regulates the expression of a subset of ISGs that play important roles in antiviral and immune responses.

*Dose Dependence and Kinetics of NFκB-dependent ISGs*—To further investigate the induction of ISGs that were negatively regulated by NFκB, quantitative real-time PCR assays were performed for *Ifi47*, *Tap1*, and *Mx1* using RNA from WT and NFκB-KO MEFs treated with IFNβ. Consistent with the microarray results, *Mx1*, *Ifi47*, and *Tap1* (Fig. 1) were induced by IFNβ in a dose-dependent manner to higher expression levels in NFκB-KO cells than in WT cells. Similarly, we showed previously that *Mx1* and *Nmi* were also induced more in NFκB-KO cells than in WT cells by IFN in a dose-dependent manner (6).

We also examined the time course of IFN induction of these genes. *Ifi47*, *Tap1*, and *Mx1* (Fig. 2*A*) were induced more rapidly in NFκB-KO cells compared with WT cells. For example in WT MEFs, *Mx1* was induced by 2 h of IFN treatment and reached a maximal induction level of ~15-fold after 4 h. In sharp contrast, *Mx1* was induced ~10-fold after 30 min and ~220-fold after 4 h of IFN treatment in NFκB-KO cells. Moreover, the changes in the mRNA levels were accompanied by changes in the protein levels for Tap1 and Mx1 proteins (Fig. 2*B*). The effect of NFκB on regulation of these ISGs is specific, since the expression profile of another ISG, *IRF1*, was not regulated by NFκB (Fig. 2*A*). In addition, the effects of NFκB on IFN-induced gene expression did not reflect altered JAK-STAT signaling, since STAT2 activation was similar in WT and NFκB-KO MEFs (Fig. 2*B*). These results suggested that NFκB selectively decreased and delayed the transcription of a subset of ISGs.

*The Binding of p50 and p65 to the Promoters of NFκB-dependent ISGs*—To investigate which NFκB proteins regulated the transcription of *Ifi47*, *Tap1*, and *Mx1*, we performed ChIP assays. Although STAT proteins were not basally bound to the promoters of *Ifi47*, *Tap1*, and *Mx1*, IFN treatment induced the binding of STAT1 and STAT2 to these promoters in WT and NFκB-KO MEFs between 15 and 60 min of IFN treatment (Fig. 3, *A–C*). This result was expected, since the binding of these STAT proteins is necessary for IFN-induced activation of ISG transcription. In contrast to STAT proteins, the p50 NFκB protein was basally bound to the promoter of these ISGs in WT MEFs, while p65 was basally bound to *Ifi47* and *Tap1* promoters. Since the genes for p50 and p65 were both deleted in NFκB-KO mice, neither protein was found bound to the promoter of these ISGs in NFκB-KO MEFs. Interestingly, in NFκB-KO MEFs IFN treatment resulted in the recruitment of IRF1 to the promoters of all three ISGs, and IRF1 recruitment closely correlated with the rapid and enhanced induction of the genes upon IFN treatment. Although IRF1 itself is an ISG, we found that *IRF1* expression was not NFκB-regulated; IFN induction of *IRF1* was similar in WT and NFκB-KO MEFs as determined by microarray analysis (~6-fold) or quantitative real-time PCR (Fig. 2*A*). Taken together these results demonstrate that NFκB directly binds to the promoters of a subset of ISGs and thereby inhibits their induction by IFN, perhaps by inhibiting recruitment of IRF1 to their promoters.




FIGURE 4. **IFN-induced antiviral response to influenza infection in WT and NFκB-KO fibroblasts.** To determine the ability of IFNβ to reduce virus titers in influenza-infected WT and NFκB-KO MEFs, fibroblasts were preincubated overnight with IFNβ and infected with influenza PR8 virus, and at 24 h the virus yield was assayed by plaque formation (9). Viral titers in untreated WT and NFκB-KO MEFs were $9.5 \pm 4.5 \times 10^4$ and $7.6 \pm 2.2 \times 10^4$ plaque-forming units/ml, respectively.

p50 was bound to the promoters of all three ISG promoters and correlated with diminished ISG expression. Therefore, we examined the effect of the p50 protein alone on the induction of NFκB-regulated ISGs in MEFs derived from p50 knock-out mice. As shown in Fig. 1, *Ifi47*, *Tap1*, and *Mx1* were induced by IFNβ to higher expression levels in p50-KO than in either NFκB-KO cells or in WT cells. These results suggest that p50 is the predominant negative regulator of these ISGs.

*NFκB Dampens the Antiviral and Immunomodulatory Activity of IFN against the Influenza Virus*—The NFκB-regulated ISG *Mx1* has selective antiviral activity in mice against the influenza virus (16). Therefore, we investigated whether NFκB modulated the anti-influenza activity of IFN. WT and NFκB-KO MEFs were infected with the PR8 strain of influenza A in the absence or presence of different concentrations of IFN, and viral replication was measured after 24 h. As shown in Fig. 4, IFN (100 units/ml) results in only a 10-fold reduction in virus titer in WT MEFs. However, a 100-fold lower IFN concentration (1 unit/ml) was sufficient to induce equivalent antiviral effects in NFκB-KO as compared with WT MEFs.

The NFκB-regulated ISG *Tap1* is required for antigen presentation of an immunodominant influenza viral epitope (18). Since IFN also modulates this facet of the host immune response, we next determined the effect of IFN on influenza-specific MHC class I antigen presentation in WT and NFκB-KO MEFs. Using a T cell hybridoma specific for the immunodominant $D^b$NP-366 influenza peptide as responder cells, we determined that antigen presentation levels were significantly enhanced by IFN treatment in NFκB-KO MEFs as compared with WT cells (Fig. 5). Taken together, these results indicate that NFκB dampens several functionally important IFN activities.

## DISCUSSION

The purpose of the present study was to characterize the role of NFκB in the biological actions of IFN using a functional genomic approach. We show that NFκB negatively regulates the induction of a subset of ISGs by IFN and that NFκB suppresses the antiviral and immunomodulatory activities of IFN in the context of influenza virus infection. Both IFN and NFκB play critical roles in the host defense to various pathogens. However, the role of NFκB in the biological functions of IFN is relatively undefined. We previously found that the deficiency of p65 and




FIGURE 5. **IFN-induced immune response to influenza infection in WT and NFκB-KO fibroblasts.** To determine the effect of IFN on the immune response to influenza virus, the MHC class I levels (10) (*A*) or MHC class I antigen presentation (11) (*B*) on control and IFN-treated MEFs was determined. The data represent the average of duplicate determinations from three independent experiments.

p50 NFκB subunits sensitized MEFs to antiviral action of type I IFNs against vesicular stomatitis virus (6). Indeed, NFκB increases the susceptibility of human cells to influenza virus infection (19). Our findings provide a possible molecular mechanism for this observation whereby p50-containing NFκB dimers basally inhibit a subset of IFN antiviral genes via binding directly to their promoters.

The role of the JAK-STAT pathway in gene induction and in the generation of many of the biological effects of IFN is firmly established. However, it is now apparent that the activation of the JAK-STAT pathway alone is insufficient to account for all of the biological actions of IFNs. Some of these pathways operate independently of the JAK-STAT pathway, while other pathways may cooperate with STATs to regulate the transcription of target genes. For example, although the role of IRF9 together with the STAT1/STAT2 dimer in the transcriptional regulation of ISGs is well described, other IRF proteins can also act as transcriptional activators and/or repressors of IFN-regulated genes (2). In addition, the p300/CBP co-activators can interact with STAT proteins to regulate ISG transcription (20, 21).

We show that, although NFκB is basally bound to ISG promoters, the IFN-induced binding of STAT1 and STAT2 to these promoters was unimpeded. Therefore, NFκB does not negatively regulate ISG induction through affecting STAT binding to ISG promoters. However, NFκB proteins appear to modulate IRF1 promoter binding. IRF1 is also an IFN-induced transcriptional activator of ISG expression (22). We show that in NFκB-KO MEFs, but not in WT MEFs, IRF1 is recruited to ISG promoters upon IFN treatment, and this recruitment closely correlates with the more rapid and enhanced ISG expression in NFκB-KO cells. Moreover, other co-activators of ISG expression (*i.e.* p300/CBP) are also bound to ISG promoters in the absence of NFκB proteins.[3] Therefore, NFκB may negatively regulate ISG expression by directly or indirectly inhibiting the promoter binding of co-activators of ISG expression.

The notion that NFκB suppresses transcription is contrary to its classical role of stimulating the transcription of target genes. However, several recent studies indicate that NFκB may down-regulate cellular responsiveness to specific cytokines. For example, tumor necrosis factor-mediated JNK signaling is enhanced in NFκB-KO mice (23, 24). Moreover, we previously showed that the IFN-induced expression of some ISGs (*Mx1* and *Nmi*) is negatively regulated by NFκB, while the expression of other ISGs, such as *Ifit1* and *Isg15*, is enhanced by NFκB (6). In the present study, we show that NFκB has opposing effects on different ISGs that map to a single genetic locus. For example, the induction by IFN of *Gbp1* and *Gbp2*, which are located adjacent to one another on mouse chromosome 6, are negatively and positively regulated by NFκB, respectively (Table 1). Similarly, the induction of *Tap1* and *Tap2*, which are adjacent to one another on mouse chromosome 17, is also affected in opposite directions by NFκB (Table 1). These results suggest that NFκB may act as a transcriptional switch to fine-tune the expression of neighboring ISG family members in a locus. It will be important to determine the cellular consequences of this regulatory pathway with regard to the specific functions of Gbp and Tap family proteins.

The ability to integrate multiple signaling pathways to achieve unique responses is a critical requirement for development and homeostasis in all metazoans (25). In this study, we have characterized the relationship of the classical JAK-STAT pathway to NFκB pathway in the transcriptional regulation of *Ifi47*, *Tap1*, and *Mx1*. Moreover, we demonstrate that NFκB regulates the antiviral activity of IFN and the promotion of T cell activation. Type I IFNs are broadly used in clinical treatment of viral infections, multiple sclerosis, and cancer. We show that the efficacy of IFN as an antiviral agent against influenza virus is significantly enhanced in NFκB-KO MEFs. Interestingly, NFκB inhibitors are currently used to treat inflammatory diseases and autoimmune disease. Thus, we propose that the combination of IFN and NFκB inhibitors may be used to maximize the therapeutic benefit of IFN in the treatment of human disease while minimizing the dosage and possibly its undesirable side effects.

*Acknowledgments—We thank Dr. Otto Haller (University of Freiburg, Freiburg, Germany), Dr. Darren Baker (Biogen-Idec, Cambridge, MA), and Drs. David Baltimore (California Institute of Technology, Pasadena, CA) and Alexander Hoffmann (University of California-San Diego, La Jolla, CA) for kindly providing anti-Mx1 antibody, IFNβ, and MEF cultures, respectively. We also thank Dr. Dennis Carrigan and Dr. Jong-Gwam Kim for advice and technical support.*

[3] L. Wei, R. Homayouni, and L. M. Pfeffer, unpublished observations.

## REFERENCES

1. Darnell, J. E. J., Kerr, I. M., and Stark, G. R. (1994) *Science* **264,** 1415–1421
2. Barnes, B., Lubyova, B., and Pitha, P. M. (2002) *J. Interferon Cytokine Res.* **22,** 59–71
3. Yang, C. H., Murti, A., Basu, L., Kim, J. G., and Pfeffer, L. M. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97,** 13631–13636
4. Yang, C. H., Murti, A., Pfeffer, S. R., Kim, J. G., Donner, D. B., and Pfeffer, L. M. (2001) *J. Biol. Chem.* **276,** 13756–13761
5. Hayden, M. S., and Ghosh, S. (2004) *Genes Dev.* **18,** 2195–2224
6. Pfeffer, L. M., Kim, J. G., Pfeffer, S. R., Carrigan, D. J., Baker, D. P., Wei, L., and Homayouni, R. (2004) *J. Biol. Chem.* **279,** 31304–31311
7. Arduini, R. M., Li, Z., Rapoza, A., Gronke, R., Hess, D. M., Wen, D., Miatkowski, K., Coots, C., Kaffashan, A., Viseux, N., Delaney, J., Domon, B., Young, C. N., Boynton, R., Chen, L. L., Chen, L., Betzenhauser, M., Miller, S., Gill, A., Pepinsky, R. B., Hochman, P. S., and Baker, D. P. (2004) *Protein Expression Purif.* **34,** 229–242
8. Beg, A. A., and Baltimore, D. (1996) *Science* **274,** 782–784

9. Govorkova, E. A., Fang, H. B., Tan, M., and Webster, R. G. (2004) *Antimicrob. Agents Chemother.* **48,** 4855–4863
10. Belz, G. T., Xie, W., Altman, J. D., and Doherty, P. C. (2000) *J. Virol.* **74,** 3486–3493
11. Chen, W., Calvo, P. A., Malide, D., Gibbs, J., Schubert, U., Bacik, I., Basta, S., O'Neill, R., Schickli, J., Palese, P., Henklein, P., Bennink, J. R., and Yewdell, J. W. (2001) *Nat. Med.* **7,** 1306–1312
12. Hosack, D. A., Dennis, G., Jr., Sherman, B. T., Lane, H. C., and Lempicki, R. A. (2003) *Genome Biol.* **4,** R70
13. Taylor, G. A., Feng, C. G., and Sher, A. (2004) *Nat. Rev. Immunol.* **4,** 100–109
14. Anderson, S. L., Carton, J. M., Lou, J., Xing, L., and Rubin, B. Y. (1999) *Virology* **256,** 8–14
15. Lee, S. H., and Vidal, S. M. (2002) *Genome Res.* **12,** 527–530
16. Haller, O., Frese, M., and Kochs, G. (1998) *Rev. Sci. Tech.* **17,** 220–230
17. Ploegh, H. L. (2000) *Nutr. Rev.* **58,** S25–S30; S63–S73
18. Uger, R. A., and Barber, B. H. (1997) *J. Immunol.* **158,** 685–692
19. Nimmerjahn, F., Dudziak, D., Dirmeier, U., Hobom, G., Riedel, A., Schlee, M., Staudt, L. M., Rosenwald, A., Behrends, U., Bornkamm, G. W., and Mautner, J. (2004) *J. Gen. Virol.* **85,** 2347–2356
20. Horvath, C. M., and Darnell, J. E. (1997) *Curr. Opin. Cell Biol.* **9,** 233–239
21. Zhang, Y., Takami, K., Lo, M. S., Huang, G., Yu, Q., Roswit, W. T., and Holtzman, M. J. (2005) *J. Biol. Chem.* **280,** 34306–34315
22. Pine, R. (1992) *J. Virol.* **66,** 4470–4478
23. De Smaele, E., Zazzeroni, F., Papa, S., Nguyen, D. U., Jin, R., Jones, J., Cong, R., and Franzoso, G. (2001) *Nature* **414,** 308–313
24. Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., and Lin, A. (2001) *Nature* **414,** 313–317
25. Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K., and Rosenfeld, M. G. (2002) *Cell* **110,** 55–67